Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

inflect1on Dec. 7 at 10:45 PM

$BHC retest happened, but bad close. 6.3 likely

0 · Reply

CleoY_Hwntz60 Dec. 5 at 9:40 PM

$BHC turnaround-style healthcare tape, surprises can trigger sharp re-ratings

0 · Reply

FU2 Dec. 5 at 7:11 PM

$BHC might be buying at $6 flat next week again. Amazing the control of price movement here. Total fuckery

0 · Reply

greyfox Dec. 5 at 3:43 PM

$BHC why? Only thing special today is that a small number of options expire. Can you expand on your thesis.

0 · Reply

macd87 Dec. 5 at 3:37 PM

$BHC Today is Friday, nothing is going to happen

0 · Reply

greyfox Dec. 5 at 3:34 PM

$BHC now, now...lets get back to buying this as this little dip has provided a good buying window.

0 · Reply

marti837 Dec. 5 at 9:57 AM

$BHC buy

0 · Reply

GreedyBunny Dec. 4 at 10:29 PM

$BHC Cooper adds a new board chair. This might be because of the latest activist pressure. Things getting interesting 🤔

2 · Reply

inflect1on Dec. 4 at 10:08 PM

$BHC last one. Maybe worth a gamble soon, retest 7 into eow?

0 · Reply

Steelrunner56 Dec. 4 at 8:16 PM

$BHC got $7.5 let get 8

1 · Reply

Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:02 PM EST - 6 days ago

Why Bausch Health Companies Stock Rocketed 11% Higher Today

Dec 1, 2025, 4:34 PM EST - 6 days ago

Biggest Stock Movers Today, Dec. 1: BHC, SMR, & More

ASH BMNR SMR

Dec 1, 2025, 7:00 AM EST - 6 days ago

Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China

Nov 24, 2025, 7:05 AM EST - 13 days ago

Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

Nov 18, 2025, 7:00 AM EST - 19 days ago

Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 8:18 AM EST - 24 days ago

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Nov 13, 2025, 7:00 AM EST - 24 days ago

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Nov 11, 2025, 7:07 AM EST - 26 days ago

Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path

Nov 5, 2025, 8:00 AM EST - 4 weeks ago

Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Nov 3, 2025, 4:30 PM EST - 4 weeks ago

Bausch + Lomb to Hold Investor Day on Nov. 13

Oct 31, 2025, 7:45 AM EDT - 5 weeks ago

Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results

Oct 29, 2025, 8:26 PM EDT - 5 weeks ago

Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 5 weeks ago

Bausch Health Announces Third Quarter 2025 Results

Oct 20, 2025, 10:57 AM EDT - 6 weeks ago

Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb

Oct 9, 2025, 7:00 AM EDT - 2 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 2 months ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 2 months ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 2 months ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 12:04 PM EDT - 3 months ago

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 8:35 AM EDT - 3 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 3 months ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 26, 2025, 8:00 AM EDT - 3 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 3 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 3 months ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 4 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 12, 2025, 1:02 PM EDT - 4 months ago

Why Bausch Health Stock Surged By Nearly 20%

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 11:30 PM EDT - 4 months ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 4 months ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 4 months ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 4 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 4 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 4 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 4 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 5 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 5 months ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 5 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 2, 2025, 7:00 AM EDT - 5 months ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jun 26, 2025, 4:30 PM EDT - 5 months ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 22, 2025, 5:00 AM EDT - 6 months ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Jun 18, 2025, 11:01 AM EDT - 6 months ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Jun 16, 2025, 4:04 AM EDT - 6 months ago

Repricing Potential Driven By Deleveraging

Jun 4, 2025, 6:59 AM EDT - 6 months ago

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

May 21, 2025, 9:45 AM EDT - 7 months ago

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

May 21, 2025, 6:59 AM EDT - 7 months ago

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

May 14, 2025, 4:15 PM EDT - 7 months ago

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

inflect1on Dec. 7 at 10:45 PM

$BHC retest happened, but bad close. 6.3 likely

0 · Reply

CleoY_Hwntz60 Dec. 5 at 9:40 PM

$BHC turnaround-style healthcare tape, surprises can trigger sharp re-ratings

0 · Reply

FU2 Dec. 5 at 7:11 PM

$BHC might be buying at $6 flat next week again. Amazing the control of price movement here. Total fuckery

0 · Reply

greyfox Dec. 5 at 3:43 PM

$BHC why? Only thing special today is that a small number of options expire. Can you expand on your thesis.

0 · Reply

macd87 Dec. 5 at 3:37 PM

$BHC Today is Friday, nothing is going to happen

0 · Reply

greyfox Dec. 5 at 3:34 PM

$BHC now, now...lets get back to buying this as this little dip has provided a good buying window.

0 · Reply

marti837 Dec. 5 at 9:57 AM

$BHC buy

0 · Reply

GreedyBunny Dec. 4 at 10:29 PM

$BHC Cooper adds a new board chair. This might be because of the latest activist pressure. Things getting interesting 🤔

2 · Reply

inflect1on Dec. 4 at 10:08 PM

$BHC last one. Maybe worth a gamble soon, retest 7 into eow?

0 · Reply

Steelrunner56 Dec. 4 at 8:16 PM

$BHC got $7.5 let get 8

1 · Reply

greyfox Dec. 4 at 6:18 PM

$BHC there are vey few options...ie see open interest. Options most popular are the 19th expiry so dont see much action this Friday but in 2 weeks time. I think this will move to $8 for Friday.

0 · Reply

FU2 Dec. 4 at 6:11 PM

$BHC these boys like there option money. My guess we hang around $7.50 till close on Friday. Still a leash on this ticker. Headed in the right direction at least this push.

0 · Reply

FU2 Dec. 4 at 5:18 PM

$BHC BHC is not near its valuation alone at this price. Just think when a move is made with BLCO. 4-5 bagger from here. Buy and hold. 2026 is going to be big. Maybe even before!!!

0 · Reply

JordanBelfortz Dec. 4 at 5:10 PM

$BHC big wall at 7.5, move above and we’re goin to 7.8, then 8

0 · Reply

greyfox Dec. 4 at 5:08 PM

$BHC holy crap..dont understand this with almost 42000 people watching this and it has a phenomenal move of 44 cents or more than 6% and yet no messages, nada. WTF? So looks like we will easily see $7.50 and so perhaps $8 possible

1 · Reply

FU2 Dec. 4 at 4:50 PM

$BHC Solta alone is worth this price. If you wait for news that BLCO sold you will miss the train. Retail is the end of the food chain. Just buy and sit on it. This will be a rocket ride higher in a blink of an eye when it happens.

0 · Reply

greyfox Dec. 4 at 4:18 PM

$BHC if you wont touch this why are you on the board...just to bust balls?

2 · Reply

btradingwarehouse Dec. 4 at 4:09 PM

$BHC ...2BULLS... ...HoooooDooor...do NOT touch it !!! ... ...You are investor--->You wait for $10-12...!!! ...Above that price @BHC stops being P-bitch... ... ...You are trader--->Do whatever you know the best...!!! ... ... Stay smart strong smile ... ... Almost forgot: NEVER SELL !!!

0 · Reply

greyfox Dec. 4 at 2:58 PM

$BHC almost there for a nice gain so far. So if we break $7.25 is $7.50 out of the realm of possibility today?? WTF with this board - deader than a doorknob! Much to celebrate and much to discuss yet only crickets??

3 · Reply

greyfox Dec. 4 at 2:43 PM

$BHC its starting again and on the right foot. Lets see if we can crack $7.25 today. All in and back up the truck!

0 · Reply

marti837 Dec. 4 at 8:54 AM

$BHC Icahn couldn't turn it around, can Paulson? Disappointing

1 · Reply

FU2 Dec. 3 at 9:01 PM

$BHC big trade end of day

0 · Reply

Market Cap	2.57B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.94
Forward PE	1.91
Profit Margin	-0.48%
Debt to Equity Ratio	59.11

Volume	2,157,500
Avg Vol	2,448,822
Day's Range	N/A - N/A
Shares Out	370.86M
Stochastic %K	61%
Beta	0.41
Analysts	Hold
Price Target	$7.17